Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

Patricia Maiso1, Daisy Huynh1, Michele Moschetta3, Antonio Sacco1, Yosra Aljawail1, Yuji Mishima1, John M. Asara2, Aldo M. Roccaro1, Alec C. Kimmelman3, and Irene M. Ghobrial1

Abstract

Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow. The main cause of resistance in myeloma is the minimal residual disease cells that are resistant to the original therapy, including bortezomib treatment and high-dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in multiple myeloma cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain-of-function studies using LDHA or HIF1A induced resistance in bortezomib-sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.

Introduction

Cellular metabolic versatility is essential for the maintenance of energy production throughout a range of oxygen concentrations (1). Metabolic changes occurring in cancer cells are considered to be fundamental for the transformation of normal cells into cancer cells. A common property of invasive cancers is an altered glucose metabolism or glycolysis (1). Glycolysis converts glucose into pyruvate and in normal cells, this process is inhibited by the presence of oxygen, which allows mitochondria to oxidize pyruvate to CO2 and H2O. This inhibition is termed as the "Pasteur effect" (2). Conversion of glucose to lactic acid in the presence of oxygen is known as aerobic glycolysis or the "Warburg effect" and the increase of aerobic glycolysis is often observed in tumor cells (3–5).

One of the most recognized reasons for altered tumor metabolism is hypoxia in the tumor microenvironment (6, 7). Cells respond to the hypoxic microenvironment with the activation of hypoxia-inducible factor 1 (HIF1) transcription factor. The net result of hypoxic HIF1 activation is to shift energy production by increasing glycolysis and decreasing mitochondrial function (6). The largest functional group of genes consistently regulated by HIF1 is associated with glucose metabolism. HIF1 increases the expression of the glucose transporters, enzymatic breakdown of glucose into pyruvate and enzymes involved in the pyruvate metabolism as well as lactate production (8, 9). Although HIF1 was initially identified because of its response to low O2 concentrations, it is now apparent that HIF1 can be regulated by other factors such as oncogene activation (RAS, MYC, and PI3K) or loss of tumor suppressors, including VHL (von Hippel–Lindau) or PTEN, leading to increased glycolysis, angiogenesis, and drug resistance (10–12).

Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow. The introduction of novel agents, including bortezomib in combination with autologous stem cell transplantation, has led to a significant advancement in the treatment of patients, leading to complete response in many patients. Unfortunately, most patients ultimately relapse due to the presence of surviving tumor cells at the minimal residual disease (MRD) state, suggesting the presence of drug resistance within specific niches in the bone marrow. The bone marrow has heterogeneous areas of hypoxia and these specific niches are altered during chemotherapy and radiotherapy (1). We hypothesize that hypoxia in specific bone marrow niches regulates the maintenance of MRD cells that are resistant to treatment and have the capability to induce relapse. We sought to investigate the mechanism underlying this drug resistance through the cellular metabolic profile of multiple myeloma cells in normoxic and hypoxic conditions. Our results reveal unprecedented features of multiple myeloma cells metabolism and further demonstrate that LDHA and HIF1A are valid targets to prevent multiple myeloma drug resistance and progression in vivo.
Materials and Methods

Cells

Multiple myeloma cell lines MM1S, H929, and RPMI8226 (were kindly provided by Prof. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain). Cell lines were cultured in RPMI1640 medium with L-glutamine and supplemented with antibiotics (penicillin at 100 U/mL, streptomycin at 100 μg/mL) and 10% FBS. The luciferase (luc)-expressing MM1S-GFP/luc cell lines were generated by retroviral transduction with the pGC-gfp/luc vector (kind gift of Dr. A. Kung, Dana-Farber Cancer Institute, Boston, MA).

Growth inhibition assay

The inhibitory effect of different drugs was assessed by measuring MTT (Chemicon International) dye absorbance, as previously described (13, 14).

Cell cycle and apoptosis assays

Cell-cycle analysis was profiled by flow cytometry using propidium iodide (PI) staining (5 μg/mL, Sigma Chemical) after 24 hours culture in normoxic or hypoxic conditions. Apoptosis was measured using Annexin V–FITC staining and flow cytometric analysis according to the manufacturer’s protocol.

Gene expression profile

Gene expression profile has been performed on MM1S using Affymetrix Human Genome U133 Plus 2.0 Array, (GEO accession number: GSE52315). Comparison between normoxia (n = 3) and hypoxia (n = 3) was performed by using dChip (2-fold change; P < 0.05). Differentially expressed genes were classified using dChip software. Gene Set Enrichment Analysis (GSEA) was performed using the publicly available desktop application from the Broad Institute (http://www.broad.mit.edu/gsea/software/software_index.html). The gene sets database used was that of functional sets, s2.symbols.gmt. P values were calculated by permuting the genes 1,000 times. The classic enrichment statistic was selected. The gene expression datasets from Schaefer CF and colleagues provided in the Pathway Interaction Database (NCI and Nature Publishing Group) were used for HIF1A and HIF2A analysis in GSEA (15). The gene expression datasets REACTOME_ GLUCOSE_ METABOLISM and sacrience_3 minutes after the injection, using Xenogen In Vivo Minescence imaging. Mice were injected with 75 mg/kg of luciferase (luc), MM1S-GFP/luc-shHIF1A, or MM1S-GFP/luc-shLDHA. Mice were treated with bortezomib, 0.75 mg/kg in PBS once weekly by intraperitoneal injection; Hypoxyprobe Store). After 4 hours, bone marrow was isolated from one femur by flushing with cold PBS and prepared for RNA isolation as described, the other femur was used for IHC.

In vivo studies

Six-week-old female SCID-beige mice from Charles River Laboratories were i.v. implanted with 100 μL of 5 × 10^6 MM1S-GFP/luc-scramble, MM1S-GFP/luc-shHIF1A, or MM1S-GFP/luc-shLDHA. Mice were treated with bortezomib, 0.75 mg/kg in PBS once weekly by intraperitoneal injection beginning 10 days after tumor implantation until moribund. Mice with different stages of tumor development based on tumor size detected by bioluminescence (BLI) were treated with the hypoxia marker pimonidazole hydrochloride (PIMO; 100 mg/kg by intraperitoneal injection; Hypoxyprobe Store). After 4 hours, bone marrow was isolated from one femur by flushing with cold PBS and prepared for RNA isolation as described, the other femur was used for IHC.

Immunohistochemistry

In the in vivo model, femurs were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with hematoxylin of a total of 289 endogenous water soluble metabolites for steady-state analyses of samples.

Hexokinase activity and lactate measurement

Hexokinase activity was measured with the Hexokinase Assay Kit (Abcam) and cellular lactate levels were measured using the Lactate Colorimetric Assay Kit (Biovision) according to the manufacturer’s instructions.

RNA purification, reverse transcription, and quantitative RT-PCR

Total RNA was prepared with QiAzo1 reagent (Invitrogen) according to the manufacturer’s instructions. One microgram of total RNA was reverse transcribed using SuperScript III First Strand Synthesis (Invitrogen). Diluted cDNAs were analyzed by real-time PCR using SYBR Green I Master Mix on Lightcycler 480 (Roche) on an ABI Prism 7900 Fast instrument. The level of gene expression was normalized to 18S. The primer sequences are provided in Table 1.

Table 1. Primer sequences

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers</th>
</tr>
</thead>
</table>
| human HIF1A | F: TTGGACACTGGTG6GCTCATTAC  
R: TGAGCTGTCTGTGATCCAGCAT  
T: RAGAGCAGCCCTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA...
and eosin (H&E) in accordance with standard procedures. Immunohistochemistry was performed using antibodies against Mab1 (Hypoxprobe Store), HK2 (Cell Signaling Technology) and LDHA (Cell Signaling Technology) according to the manufacturer’s instructions. All multiple myeloma biopsies were evaluated at DFCI and the histologic diagnosis was based on H&E. Histologic IHC images were obtained with the Olympus AH2 microscope camera from Center Valley. Image acquisition and processing software were performed using an Olympus DP12 camera and software.

**Knockdown constructs**

Stable knockdowns of HIF1A, HIF2A, HK2, and LDHA were generated by lentiviral transduction of MM1S and MM1S-GFP/luc cells with five independent shRNA hairpin sequences targeting human HIF1A, HIF2A, HK2, and LDHA, respectively. A scrambled shRNA sequence was used as control (TRCN0000072212). Lentiviral shRNAs were obtained from The RNAi Consortium (TCR) collection of the Broad Institute (Cambridge, MA). The TCR numbers for the shRNA used are found in Table 2.

**Statistical analysis**

P values described in the in vitro assays are based on t tests (two-tailed; α 0.05). P values are provided for each figure.

### Results

#### Hypoxia promotes drug resistance in multiple myeloma

We first examined hypoxia-regulated pathways in primary multiple myeloma patients to test the enrichment of HIF1A and HIF2A (15) pathways in plasma cells isolated from bone marrow of normal donors and multiple myeloma patients; we analyzed the published gene expression datasets (series numbers, GSE6477 and GSE9782, respectively; refs. 16, 17). Newly diagnosed multiple myeloma patients showed an enrichment of HIF1A and HIF2A pathways compared with normal donors (Supplementary Fig. S1A), we also found an enrichment of both pathways in patients with relapsed and bortezomib-refractory myeloma compared with patients responding to bortezomib (Supplementary Fig. S1B).

We next investigated whether hypoxia plays a role in drug resistance in multiple myeloma. Given the importance of hypoxia in facilitating tumor progression and resistance to chemotherapy in solid tumors, we evaluated the effect of several conventional agents used in the treatment of multiple myeloma such as dexamethasone, melphalan, and bortezomib, either under normoxia (20% O2) or hypoxia (1% O2) in multiple myeloma cells. Our findings indicate that hypoxia inhibited the effect of bortezomib and melphalan in MM1S (Supplementary Fig. S1C), RPMI8226 (Supplementary Fig. S1D), and H929 (Supplementary Fig. S1E) cells. As hypoxia has been shown to cause cell-cycle arrest and this could potentially impact therapeutic responses, we analyzed the effect of hypoxia on cell-cycle regulation and apoptosis by flow cytometry. After 24 hours, hypoxia induced G1 arrest (Supplementary Fig. S1F) but not apoptosis (Supplementary Fig. S1G) in multiple myeloma cells. However, induction of G1 arrest through serum starvation (Supplementary Fig. S1H) did not impact the response to bortezomib in MM1S, RPMI8226, and H929 (Supplementary Fig. S1I). Carfilzomib showed similar activity to bortezomib on MM1S, RPMI8226, and H929 cells (Supplementary Fig. S1I). Therefore, the drug resistance effect observed with hypoxia was not due to the G1 arrest observed in hypoxic conditions. To further confirm the effect of hypoxia, we pretreated the cells for 12 hours under normoxic or hypoxic conditions and then added the therapeutic agent for an additional 24 hours under both normoxia and hypoxia. We found multiple myeloma cells responded to bortezomib treatment under normoxic conditions but not under hypoxia even with previous culture in normal oxygen levels (Supplementary Fig. S1K).

**Metabolic reprogramming delineates a role for drug resistance in myeloma cells**

Because one of largest functional groups regulated by HIF1 is associated with glucose metabolism, we hypothesized that changes in cell metabolism could serve as the main factor of drug resistance in multiple myeloma cells. To examine mechanisms underlying metabolism-associated drug resistance, we performed targeted metabolomic profiling in MM1S cells before and after bortezomib treatment under both normoxic and hypoxic conditions. The metabolic profile of hypoxic cells demonstrated a clear shift when compared with normoxic cells; however, cells treated with bortezomib were similar to their nontreated counterparts in both conditions (Fig. 1A). In hypoxic cells, intermediates of TCA cycle and mitochondrial electron transport chain were reduced, whereas intermediates of glycolysis were elevated (Fig. 1B).

To determine specific metabolic changes are due to hypoxia and not to the G1 cell-cycle arrest observed in hypoxic cells, we starved MM1S cells for 12 hours and the metabolic profile of MM1S cells arrested at G1 phase showed a decrease on glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate, pyruvate, and lactate metabolites (Fig. 1C). In contrast to G1-arrested cells, hypoxic cells showed an increase in glycolysis metabolites, including pyruvate and lactate (Fig. 1C and D). To further examine metabolic alterations in hypoxic conditions, we performed gene expression profile (GEP) on MM1S under normoxic or hypoxic conditions and performed GSEA using the ranked gene list from Dchip (changes in gene expression greater than 2-fold with P value lower than 0.05 were considered significant). To identify the most significant pathways altered by hypoxia, we compared normoxic samples (n = 3) versus hypoxic samples (n = 3) and found that after 24 hours of hypoxia, 3,609 genes were deregulated (1,649 genes were upregulated in hypoxia and 1,960 genes were upregulated in normoxia; Fig. 2A). The main pathways altered by hypoxic culture
Figure 1.
Metabolic profiles of multiple myeloma (MM) cells reflect an increase in glycolysis in response to hypoxia. A, unsupervised hierarchical clustering was performed using the 289 metabolites whose intensity varied across the 12 samples. Samples were clustered using Metaboanalyst software. For each metabolite, data were median centered (white), with the lowest and highest intensity values in blue and red, respectively. B, metabolite enrichment pathway overview. C, heatmap comparing relative levels of metabolites on multiple myeloma cells in response to serum starvation for 12 hours and to hypoxia for 24 hours. Heatmaps show the relative levels of starved cells (top) and hypoxic cells (bottom) in comparison with MM1S-control-normoxic cells. D, schema illustrating the specific metabolites that are increased (red) or decreased (blue) in multiple myeloma cells in response to hypoxia after 24 hours.
Figure 2.
GEPs evidence an increase in glycolytic and lactate enzymes in response to hypoxia. A, gene pattern comparative marker showing upregulated genes in normoxic and hypoxic multiple myeloma (MM) cells; n = 3 samples in each condition. B, microarray data were analyzed using GSEA software to identify functionally related groups of genes (gene sets) with statistically significant enrichment. The figure shows the enrichment plot and the top 35 enriched genes for hypoxia-related set. NMX, normoxia; HPX, hypoxia. C, GSEA enrichment plots for glucose metabolism and TCA cycle in normoxia versus hypoxia conditions in multiple myeloma cells. D, GSEA enrichment plots for glucose metabolism and TCA cycle in newly diagnosed (ND) patients versus normal bone marrows (NBM; GSE6477) and in relapsed versus newly diagnosed (ND) myeloma patients (GSE9782). E, hexokinase activity in MM1S cells treated with bortezomib (5 nmol/L) under normoxic and hypoxic conditions for 24 hours. F, lactate levels in MM1S cells treated with bortezomib (5 nmol/L) under normoxic and hypoxic conditions for 24 hours.

* P < 0.05; ** P < 0.005; and *** P < 0.0005. FDR, false discovery rate.
were those involved in glucose metabolism (including glycolytic enzymes; Fig 2B and C) and TCA cycle (Fig 2C). We also validated our data on additional cell lines, and showed that similar changes on key metabolic genes (HK2, PFKFB3, PFKFB4, and LDHA) were observed among all the cell lines tested MM1S, H929, and RPMI8226 (Supplementary Fig S2A–S2C).

Glucose metabolism gene set was also enriched in the datasets comparing plasma cells from newly diagnosed multiple myeloma patients with normal donors and in plasma cells from relapsed myeloma patients versus newly diagnosed (ND) multiple myeloma (Fig 2D).

Importantly, hypoxia regulates expression of HIF1A target genes that are critical for increased glucose uptake and catabolism such as hexokinase II (HK2) and lactate dehydrogenase A (LDHA; refs. 19–21). Both genes were significantly upregulated in our expression datasets (FC = 2.1 and FC = 5.2, respectively). To test whether bortezomib affects the enzymatic activities of HK2 and LDHA, we measured the hexokinase and lactate activities in cells treated with bortezomib under normoxic and hypoxic conditions. Bortezomib was able to decrease the hexokinase activity even under hypoxic conditions (Fig 2E) but not the lactate activity that was significantly increased under hypoxic conditions (Fig 2F). We found that bortezomib inhibited HK2 activity of multiple myeloma cells under hypoxic conditions but not lactate activity, suggesting that LDHA may play a role in modulating drug resistance of multiple myeloma cells in hypoxia.

**HIF1A knockdown decreases lactate levels and partially restores the effect of bortezomib under hypoxic conditions.**

HIF1A is the main pathway to induce glycolysis and lactate production during hypoxia (20, 22, 23). Under low oxygen conditions, HIF1A is stabilized and promotes transcription of several genes critical for the cellular response to hypoxia (10). We hypothesized that cells lacking HIF1A will fail to upregulate glycolytic enzymes and lactate production in response to hypoxia and will render them more sensitive to chemotherapy. To test this hypothesis, we performed HIF1A and HIF2A loss-of-function studies in multiple myeloma cells. HIF1A and HIF2A knockdown efficiencies were evaluated using qRT-PCR and Western blot analysis (Supplementary Fig S3A–S3C). The metabolic profile of MM1S-HIF1A knockdown cells demonstrated a clear shift away from glycolytic metabolism when compared with MM1S-scramble under normoxic conditions (Fig 3A), and a similar shift occurred under hypoxic conditions (Fig 3A). In MM1S-HIF2A knockdown, intermediates of glycolysis were slightly reduced, but pyruvate and lactate levels increased after hypoxia exposure (Fig 3A). The levels of TCA cycle intermediates decreased in HIF1A and HIF2A knockdowns compared with MM1S-scramble after either normoxia or hypoxia exposures (Fig 3B).

To confirm that the HIF1A and HIF2A knockdown metabolites patterns reflected a shift in glycolysis and mainly in lactate production, we measured hexokinase activity and lactate production in both cells under normoxic and hypoxic conditions. As expected, HIF1A knockdown cells showed a reduction in hexokinase activity under hypoxic conditions similar to normoxic levels (Fig 3C) and a significant decrease in lactate production in both normoxic and hypoxic levels compared with the scramble (Fig 3D). Hexokinase and lactate activities did not change in HIF2A knockdown cells (Fig 3C and D).

Consistent with the metabolite profile pattern and the reduction of hexokinase and lactate levels, the HIF1A knockdown partially overcomes drug resistance to bortezomib (Fig 3E) and melphalan (Supplementary Fig S3D) after hypoxia exposure. However, HIF2A knockdown did not produce similar results, indicating that HIF2A is not essential for the induced drug resistance (Fig 3F).

To determine the *in vivo* effect of HIF1A loss, we knocked down HIF1A expression in MM1S-GFP/luc, HIF1A knockdown efficiency was evaluated by qRT-PCR (Supplementary Fig S3E). MM1S-GFP/luc-scramble (*n* = 14) and MM1S-GFP/luc-shHIF1A (HIF1A knockdown, clone 2; *n* = 14) were injected i.v. into NOD-SCID mice. After 10 days we started the treatment of each group (*n* = 7 per group), 28 mice were treated with vehicle (*n* = 14) or bortezomib (0.75 mg/kg, weekly, intraperitoneally; *n* = 14). Tumor growth was measured using luciferin and BLI.

After 35 days, the scramble group showed significant tumor progression, whereas minimal tumor growth was detected in mice injected with HIF1A knockdown (Fig 3G). Mice groups injected with scramble cells and treated with bortezomib showed a delay in tumor growth, but after 35 days, the tumor growth increased reaching similar BLI signal to the control group (Fig 3G). Bortezomib showed a significant effect in the HIF1A knockdown group (Fig 3G), increasing the survival significantly compared with the nontreated group and compared with the control group treated with bortezomib (Fig 3H). Furthermore, mouse femurs were collected at day 10 and at day 35, and CD138 expression was analyzed by IHC. In concordance with our BLI data, we observed an increase of CD138 population with a strong staining in the scramble biopsies, whereas the HIF1A knockdown group remained very low even at day 35 (Fig 3I). The hypoxic state of multiple myeloma cells in the bone marrow was also examined by intraperitoneal injection of pimonidazole (PIMO) before bone marrow isolation and IHC was performed to detect HK2 and LDHA protein levels in tumor cells. Our results demonstrate that...
Maiso et al.
the increase of the hypoxic microenvironment induces the over-expression of HK2 and LDHA in plasma cells (Fig. 3J).

Loss of LDHA sensitizes multiple myeloma cells to drug effect

To better define the functional role of glycolysis pathways in drug resistance on multiple myeloma cells, we explored the expression of the glycolytic enzymes deregulated in our genes’ expression profile (GEP; Fig. 4A) and performed HK2 and LDHA loss-of-function studies on MM1S cells (Fig. 4B). HK2 and LDHA knockdown efficiency was evaluated by qRT-PCR (Supplementary Fig. S4A and S4B).

To confirm that HK2 and LDHA expression are increased in multiple myeloma, we analyzed HK2 and LDHA protein levels by IHC in plasma cells of newly diagnosed and refractory myeloma patients. Out of 20 patient samples, all samples showed high levels of HK2 and LDHA staining in tumor CD138+ plasma cells (Fig. 4C). Similarly, GEP of an independent set of CD138+ cells (16, 17) revealed that the expression of HK2 and LDHA increased with disease progression (Supplementary Fig. S4C).

We evaluated the effect of HK2 and HK2 knockdown on hexokinase activity and intracellular levels of lactate and found that knockdown of HK2 leads to inhibition of both hexokinase activity and lactate (Fig. 4D); however, LDHA knockdown showed a reduction in lactate but did not affect the cellular hexokinase activity compared with scramble control cells (Fig. 4E).

We next examined the effect of bortezomib on HK2 and LDHA knockdowns. MM1S-shHK2 (HK2 knockdown) cells were sensitive to the effect of bortezomib after exposure to hypoxia (Fig. 4F), whereas the effect of bortezomib was markedly higher in MM1S-shLDHA (LDHA knockdown) under both normoxic and hypoxic conditions (Fig. 4G). We also examined the effect in response to melphalan treatment, and LDHA KD restored the effect of melphalan under hypoxic conditions (Supplementary Fig. S4D). Therefore, this effect shows that metabolism-induced drug resistance represents a common mechanism of resistance to drug therapy and not just specific to bortezomib or proteasome inhibition.

LDHA expression as well as pyruvate dehydrogenase kinase 1 (PDK1) were found to be upregulated in the GEP data analysis. Both of these enzymes can limit the use of pyruvate as a carbon source for the TCA cycle (24, 25). Indeed, our metabolomics data show an overall decrease in TCA pool sizes under hypoxic conditions (where PDK1 was upregulated by microarray analysis). To better characterize the role of LDHA in drug resistant to bortezomib, we knocked down LDHA expression in the bortezomib-resistant cell line ANBL6-BR (Supplementary Fig. S5A) and overexpressed HIF1A and LDHA in MM1S cells (sensitive to bortezomib; Supplementary Fig. S5B–S5D). In ANBL6-BR, LDHA knockdown restored the sensitivity to bortezomib (Fig. 5C) and in

HIF1A and LDHA expression are associated with drug resistance

To further confirm the dependence between HIF1A, LDHA, and drug resistance, we examined the relative levels of HIF1A and LDHA in a panel of six multiple myeloma representative cell lines: MM1S and MM1R (sensitive and resistant to dexamethasone), U266 and U266LR7 (sensitive and resistant to melphalan), and ANBL6 and ANBL6-bortezomib-resistant (BR; sensitive and resistant to bortezomib, respectively).

We found that HIF1A (Fig. 5A) and particularly LDHA (Fig. 5B) levels are upregulated in all the cell lines resistant to different drugs as compared with their drug-sensitive counterparts. To better characterize the role of LDHA in drug resistant to bortezomib, we knocked down LDHA expression in the bortezomib-resistant cell line ANBL6-BR (Supplementary Fig. S5A) and overexpressed HIF1A and LDHA in MM1S cells (sensitive to bortezomib; Supplementary Fig. S5B–S5D). In ANBL6-BR, LDHA knockdown restored the sensitivity to bortezomib (Fig. 5C) and in

**Figure 4.**
Stable loss of LDHA sensitizes multiple myeloma (MM) cells to bortezomib effect. A. heatmap comparing glycolytic enzymes expression in MM1S cells under normoxia or hypoxia. B. schematic overview of glycolytic enzymes illustrating the targeted genes. C, bone marrow biopsies from multiple myeloma patients relapsed different groups 10 days after injection. PIMO, HK2, and LDHA staining was detected by IHC. H, mice were i.v. injected with 5×10⁶ of MM1S-GFP/luc. LDHA knockdown efficiency was evaluated by qRT-PCR (Supplementary Fig. S4C). MM1S-GFP/luc-shLDHA (LDHA knockdown, clone 4; n = 14) were injected i.v. into NOD-SCID mice and treatment was initiated after 10 days. Mice were treated with vehicle (n = 7) or bortezomib (0.75 mg/kg, weekly, intraperitoneally; n = 7).

After 35 days, the tumor progression was lower in the LDHA knockdown mice compared with their controls and the LDHA knockdown group treated with bortezomib showed a significant delay in tumor growth (Fig. 4H). Survival curves showed a significant difference between the scramble and LDHA knockdown groups and bortezomib highly increased the survival percentage of the LDHA knockdown mice compared with the non-treated group and with the scramble-treated group (Fig. 4I). The observed changes may be due to an impact of HIF1A and LDHA silencing on both bone marrow homing/engraftment of multiple myeloma cells, together with a reduced multiple myeloma cell growth. These data are indeed supported by the IHC studies where a reduced human-CD138 cell infiltration was documented in those mice that were injected with HIF1A- and LDHA-silenced MM1S cells compared with the related scramble control.

Mice femurs were collected at day 10 and IHC was performed to detect PIMO, HK2, and LDHA levels. In concordance with our in vitro data, even under hypoxic conditions as demonstrated by PIMO staining, LDHA knockdown group showed a lower HK2 expression in plasma cells (Fig. 4J).
Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-associated drug resistance and the reduction of LDHA increase the effect of bortezomib not only under hypoxic conditions but also in normoxic cells.

Discussion

Targeting cancer energy metabolism has been partly elusive because of the poor understanding of metabolic phenotypes of different cancers. One of the reasons for altered tumor metabolism is the physiologic stress that exists within the tumor. The tumor microenvironment suffers from hypoxia and the net result of hypoxia-inducible transcription factors activation is to shift energy production by increasing glycolysis and decreasing mitochondrial function (6, 7).

It is well established that hypoxia and consequently HIF1A activation is associated with metastasis in solid tumors and with poor patients outcome (26–28), but the metabolic-induced phenotype driven to drug resistance has been poorly explored mainly because the lack of understanding of cellular responses to inhibition of specific enzymes involved in energy metabolism. In this study, we demonstrate that altered metabolism has important implications for tumor cell growth and drug resistance.

We find that increased HIF1A-metabolic related targets such as HK2 and LDHA are present in plasma cells from newly diagnosed multiple myeloma patients and even more upregulated in relapsed multiple myeloma patients, highlighting the importance of elevated glucose metabolism in relapsed patients compared with newly diagnosed myeloma cells. This fact is further validated by the finding of a similar response and gene expression pattern in multiple myeloma cell lines under hypoxic conditions that persist even after bortezomib treatment and by the fact that both HIF1A and LDHA are overexpressed in multiple myeloma cell lines resistant to different treatments such as dexamethasone, melphalan, and bortezomib. On the basis of this, we hypothesized that metabolic alterations play a crucial role in drug
Metabolomic Signature and Drug Resistance in Multiple Myeloma

resistance in multiple myeloma. This is most critical in the MRD state when cells can survive in a hypoxic bone marrow niche after treatment with bortezomib and high-dose melphalan in stem cell transplantation, leading to ultimate recurrence of the disease.

In this study, we demonstrate that the increase of glycolytic metabolism results in increased lactate levels in multiple myeloma cells. Importantly, we show that increased glycolysis is not a consequence of the G3 arrest that cells undergo after hypoxia conditions. Rather, hypoxia actively regulates cellular glucose metabolism by activation of glycolytic enzymes transcription as we demonstrate by GEP analysis and at the functional level by enzymatic assays. Thus, taken together, our study shows that increased glycolysis leads to chemotherapy resistance in multiple myeloma cells.

The role of dysregulated metabolism in therapeutic resistance has not been examined previously (12, 29–34). The ability to reduce chemoresistance through the inhibition of metabolic pathways would be an important research area to improve patient response to therapy. As a central energetic resource for the cell, glucose metabolism is quite complex. Many enzymes contribute to the glycolytic breakdown of glucose. In the glycolytic pathway, the first rate-limiting step is the transport of glucose across the plasma membrane through glucose transporters (GLUT family). GLUT family of proteins are often upregulated in malignant cells (35). GLUT1 inhibitors, such as W2B117 and phloretin, decrease glucose uptake and display synergistic anticancer effects in lung, colon, and breast cancer as well as in leukemia in vitro (36, 37). Under hypoxia, the GLUT1 inhibitor, phloretin, significantly enhances daunorubicin effect and overcomes hypoxia-conferring drug resistance (38). Another rate-limiting enzyme in glycolysis is HK, which has important roles in both glycolysis and apoptosis, and inhibitors of HK, such as 2-deoxyglucose (2-DG), 3-bromopyruvate (3-BrPA), and lonidamine (LND) are in preclinical and early-phase clinical trials (31). Although there are several reports showing that HK inhibitors enhance the drug response in vitro under normoxic conditions (39–41), there are no ongoing trials with HK inhibitors as a single agent due to the lack of response in vitro (42). Consistent with these data, we did not observe any effect in multiple myeloma cells treated with 2-DG, 3-BrPA, or LND under hypoxic conditions or in our in vivo model (data not shown). These findings together with the fact that bortezomib was able to decrease HK2 activity under hypoxic conditions and that our HK2 knockdown revealed a decrease in LDHA activity led us to hypothesize that the main enzyme to target in our hypoxia–drug-resistant model was LDHA. This hypothesis is further supported by the fact that both HIF1A and LDHA overexpression lead to drug resistance in MM1S, whereas LDHA knockdown sensitizes ANBL6 bortezomib-resistant cells to the effect of bortezomib. LDHA catalyzes the final step in the glycolytic pathway and has a critical role in tumor maintenance. LDHA contributes to paclitaxel/trastuzumab resistance in breast cancer (33, 34) and knockdown of LDHA increased mitochondrial respiration, decreased cellular ability to proliferate under hypoxic conditions, and suppressed tumorigenesis in tumor cells (43). In line with these data, our LDHA knockdown improves the effect of bortezomib in both normoxic and hypoxic conditions and showed a significant effect in our in vivo model.

Our in vitro experiments demonstrate that stable inhibition of HIF1A in multiple myeloma cells decreased proliferation and sensitized cells to the therapeutic effect of bortezomib. Stable depletion of HIF1A inhibited glycolysis and decreased lactate levels and this reduction of lactate remained at low levels even after the exposure to hypoxia. Reduction of HK2 and LDHA expression also increased the effect the bortezomib under hypoxic conditions; however, due to the LDHA reduction observed in our stable HK2 knockdown and due to the fact that hexokinase activity was also decreased in cells treated with bortezomib under hypoxic conditions, we proposed that LDHA could be one of the main targets to overcome drug resistance induced through hypoxia. Depletion of HIF1A and LDHA in multiple myeloma cells also restored drug sensitivity to therapeutic agents such as bortezomib in vitro. Multiple myeloma tumors with HIF1A knockdown clearly demonstrated a proliferative disadvantage compared with the scramble control tumors and a significant increase of survival in the bortezomib-treated group. LDHA knockdown significantly improved the response to bortezomib treatment; however, the overall survival in the nontreated group was similar to the scramble nontreated group. A possible explanation of the decreased proliferation in multiple myeloma tumor with HIF1A knockdown may relate to the downregulation of the entire HIF1A pathway that involves not only the effect on therapeutic response but also a decrease of proliferation and angiogenesis (28, 44, 45).

In summary, our studies reveal that regulation of tumor cell metabolism in multiple myeloma cells is essential to target drug resistance in multiple myeloma. We show that the metabolic phenotype in MRD cells induced by hypoxia leads to drug resistance through HIF1A and that specific regulation of HIF1A or LDHA can restore sensitivity to therapeutic agents such as bortezomib and melphalan and can also inhibit tumor growth induced by altered metabolism.

Disclosure of Potential Conflicts of Interest

A.C. Kimmelman receives speaker bureau honoraria from Agios and US Oncology and is a consultant/advisory board member for Astellas, Forma therapeutics, and Gilead. I.M. Ghobrial is an advisory board member for Millennium/Takeda, Bristol-Myers Squibb, Celgene, and Onyx/Amen. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: P. Maiso, I.M. Ghobrial
Development of methodology: P. Maiso, Y. Mishima, J.M. Asara, I.M. Ghobrial
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Maiso, M. Moschetta, Y. Aljawai, J.M. Asara, I.M. Ghobrial
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Maiso, M. Moschetta, Y. Aljawai, J.M. Asara, I.A. Kimmelman, I.M. Ghobrial
Writing, review, and/or revision of the manuscript: P. Maiso, A.M. Roccaro, A.C. Kimmelman, I.M. Ghobrial
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Aljawai, I.M. Ghobrial
Study supervision: P. Maiso, I.M. Ghobrial
Other (designed and performed the in vitro and in vivo functional experiments): D. Huynh
Other (performed in vitro assays): A. Sacco

Grant Support

This work was supported in part by EHA (European Hematology Association), SPORE P50 CA100707, NIH R01CA154648, Leukemia and Lymphoma Society, and Miguel Servet program from Instituto de Salud Carlos III.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 19, 2014; revised February 7, 2015; accepted February 27, 2015; published OnlineFirst March 13, 2015.
References

44. Martin SK, Diamond P, Grouthos S, Peet DJ, Zannetti AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011;25:1533–42.

Maios et al.
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

Patricia Maiso, Daisy Huynh, Michele Moschetta, et al.

Cancer Res 2015;75:2071-2082. Published OnlineFirst March 13, 2015.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-3400

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2015/03/13/0008-5472.CAN-14-3400.DC1

Cited articles This article cites 45 articles, 16 of which you can access for free at: http://cancerres.aacrjournals.org/content/75/10/2071.full.html#ref-list-1

Citing articles This article has been cited by 3 HighWire-hosted articles. Access the articles at: /content/75/10/2071.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.